To compare the intravitreal brolucizumab and bevacizumab injections for chronic central serous chorioretinopathy (cCSC).

Patients with cCSC were classified into bevacizumab and brolucizumab group. The proportion of complete resolution of subretinal fluid (SRF), best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal choroidal thickness (SFCT) were compared between the two groups.

A total of 40 eyes from 40 patients with aged 34-59y were enrolled in the study. Twenty eyes in bevacizumab group (17 males) and 20 eyes (18 males) in brolucizumab group. Comparing the proportion of complete resolution of SRF, the brolucizumab group was statistically significantly higher than the bevacizumab group (P<0.05). In 1mo, CMT was significantly reduced in the brolucizumab group compared to the bevacizumab group (265±69 vs 319±70 μm; P=0.021). However, there was no significant difference in CMT between the two groups at 2 and 3mo (P>0.05).

Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC.